Jonathan M Elkins

20PUBLICATIONS
79CO-AUTHORS
Molecular targetsCharacterisation of biological macromoleculesCheminformatics and quantitative structure-activity relationshipsBiologically active moleculesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Aug 06, 2025
Tetrahydropyrazolopyridinones as a Novel Class of Potent and Highly Selective LIMK Inhibitors.

Alex G Baldwin, David W Foley, D Heulyn Jones

|Dec 23, 2024
Discovery of MDI-114215: A Potent and Selective LIMK Inhibitor To Treat Fragile X Syndrome.

Alex G Baldwin, David W Foley, Ross Collins

|May 23, 2024
Novel Dihydropteridinone Derivatives As Potent Inhibitors of the Understudied Human Kinases Vaccinia-Related Kinase 1 and Casein Kinase 1δ/ε.

Fernando H de Souza Gama, Luiz A Dutra, Michael Hawgood

|Apr 18, 2024
Unexpected Noncovalent Off-Target Activity of Clinical BTK Inhibitors Leads to Discovery of a Dual NUDT5/14 Antagonist.

Esra Balıkçı, Anne-Sophie M C Marques, Ludwig G Bauer

|Oct 07, 2022
Comparative Analysis of Small-Molecule LIMK1/2 Inhibitors: Chemical Synthesis, Biochemistry, and Cellular Activity.

Ross Collins, Hyunah Lee, D Heulyn Jones

|Sep 03, 2021
Chemical Probes for Understudied Kinases: Challenges and Opportunities.

Ricardo A M Serafim, Jonathan M Elkins, William J Zuercher

Pageof 4